Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMA), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
Dermata Therapeutics, Inc. develops dermatologic solutions and is repositioning its business around direct-to-consumer skincare under the Tome brand. Company updates center on OTC skincare concepts, including once-weekly acne and skin renewal products that use the company's Bioneedle and Spongilla technologies, as well as intellectual-property developments for Bioneedle Delivery System applications involving dermal fillers, botulinum toxin and hyperhidrosis.
Recurring Dermata news also includes financial results, private placements and at-the-market equity activity, along with management, marketing and board developments tied to its shift from pharmaceutical development toward consumer skincare products.
Dermata Therapeutics (Nasdaq: DRMA) announced the commercial launch of the Tome Foundational Treatment, the first product under its Tome direct-to-consumer skincare brand. The once-weekly skin renewal treatment, powered by Dermata’s Bioneedle technology using 100% Spongilla lacustris, is now available for purchase at www.tomeskincare.com as a one-time one-month kit or via discounted monthly subscription.
According to Dermata, this launch marks its transition from a pre-commercial company toward a consumer-focused skincare business and is the first product in a planned portfolio leveraging Bioneedle-based formulations aimed at simplifying skincare routines while improving the appearance of skin tone and texture over time.
Dermata Therapeutics (NASDAQ: DRMA) opened preorders for Tome Foundational Treatment, its first direct-to-consumer skincare product, ahead of an expected commercial launch and initial shipping date of August 25, 2026. The once-weekly topical mask, positioned as a skin "reset," retails for $178 (about $45 per treatment), with a 10% discount for subscribers.
Each four-treatment kit includes Bioneedle™ powder, an Activator tube, and an application brush, mixed by the user immediately before use. According to Dermata, Tome will be the lead brand for a broader planned portfolio of clinically tested, professional-grade, at-home skincare products.
Dermata Therapeutics (NASDAQ: DRMA) entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, issuing 2,293,608 shares of common stock (or pre-funded warrants) plus series E and short-term series F warrants to purchase up to 4,587,216 additional shares at $1.46 per share and accompanying warrants.
The placement is expected to close on or about August 18, 2026, generating approximately $3.4 million in gross proceeds, with up to about $6.7 million in potential additional gross proceeds if all warrants are exercised for cash. Company insiders, including the CEO and CFO, are participating at a $1.47 purchase and exercise price. According to Dermata Therapeutics, net proceeds will support general corporate purposes, including consumer research, launch activities for its planned August 25, 2026 direct-to-consumer skin renewal product, licensing, potential acquisitions, and working capital. The securities are being issued in a private offering under Section 4(a)(2) and/or Regulation D, with agreed resale registration rights.
Dermata Therapeutics (NASDAQ:DRMA) reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its new Tome brand. The company expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with manufacturing and packaging completed and a social media campaign underway.
As of June 30, 2026, Dermata held $4.4 million in cash and cash equivalents versus $7.5 million at year-end 2025, and expects this to fund operations into Q4 2026. Q2 2026 research and development expenses declined to $0.2 million, while selling, general and administrative expenses rose to $2.8 million driven by higher legal, marketing, commercialization, and reallocated employee costs. Total assets were $5.3 million, equity was $3.5 million, and the company reported a Q2 2026 net loss of $3.0 million, or $(0.74) per share.
Dermata Therapeutics (NASDAQ:DRMA) plans to commercially launch its first direct-to-consumer skincare product, Tome Foundational Treatment, on August 25, 2026, with waitlist customers receiving early preorder access. The once-weekly skin renewal treatment uses Dermata’s proprietary Bioneedle™ technology, based on a wild harvested freshwater sponge, to support at-home skin resurfacing.
The four-treatment Foundational Treatment set will be sold exclusively via tomeskincare.com for $178 (about $45 per treatment) and includes Bioneedle powder, an Activator solution, and an application brush. According to Dermata, this launch marks a strategic pivot toward a consumer-focused, revenue-generating business model and is the first product in a planned Tome portfolio.
Dermata Therapeutics (Nasdaq: DRMA) reported a strategic shift toward direct-to-consumer skincare in Q1 2026, advancing its new Tome brand. The company plans to launch its once-weekly Tome Foundational Treatment in mid-2026 and is preparing a second DTC product.
Dermata raised $2.0 million in net proceeds via its ATM, ending March 31, 2026 with $6.9 million in cash and cash equivalents and expecting funding runway into Q1 2027. Q1 2026 research and development expenses declined to $0.4 million, while selling, general and administrative expenses rose to $1.5 million, reflecting marketing, audit, and legal costs.
Dermata (Nasdaq:DRMA) received notice of acceptance from the Australian Patent Office for Australian Patent Application No. 2020315876, covering topical delivery of dermal fillers using its Bioneedle Delivery System (BDS). The patent will be automatically issued three months after acceptance unless a third party files an opposition.
The acceptance would be Dermata's first patent, if issued, for BDS with dermal fillers and adds to existing allowed and issued BDS patents for botulinum toxin in the US, Australia, and Japan. The company noted a strategic shift to selling direct to skincare professionals.
Dermata Therapeutics (Nasdaq:DRMA) announced a strategic pivot to develop and commercialize direct-to-consumer skincare under the new brand Tome, planning to launch its first product, the Foundational Treatment, in mid-2026. The company reported year-end 2025 cash of $7.5 million and raised $15.4 million in gross proceeds during 2025 and early 2026, which it expects will fund operations into the first quarter of 2027. Dermata also noted a $5.3 million reduction in R&D spending versus 2024 following completion of the STAR-1 acne study and withdrew its IND for XYNGARI to focus on the DTC strategy.
Dermata (Nasdaq:DRMA) appointed Kyra Peckaitis as Vice President, Marketing to lead the launch of the new Tome skincare brand, with first commercial products expected in mid-2026. Ms. Peckaitis began March 9, 2026 and received a non-qualified option for 15,000 shares at an exercise price of $1.33 per share.
The option vests 25% after one year, then monthly over 36 months, and was granted outside the company’s shareholder-approved equity incentive plan as a board-approved inducement under Nasdaq Listing Rule 5635(c)(4).
Dermata (Nasdaq:DRMA) unveiled Tome, a consumer-facing skincare brand positioning itself as "skintech at home." The company plans to launch its first Tome product, an over-the-counter once-weekly acne and resurfacing treatment, in mid-2026. Tome is described as "Studied Skincare™," combining timeless natural ingredients with modern innovations and dermatologist study to deliver high-potency, prescription-like results without prescriptions.
The announcement frames this as a strategic shift toward direct-to-consumer products intended to become foundational in simple weekly routines for improving overall skin quality.